Quartalszahlen im Biotechsektor - 500 Beiträge pro Seite

[dolly999]

hey friends

ich bins wieder, der dolly999
Sagt mal wisst ihr wie die Zahlen von The Medicines Company ausgefallen sind? Und wie schätzt ihr die Zukunft der Aktie ein?

Ach ja und was was mit Virologic gegen Handelsende in den USA bloß los....

Nagut! Ich hoffe ihr könnt mir helfen bei der Findung von den Quartalszahlen von MDCO! Wenn ihr richtige Helden sein wollt, dann wäre es geil, wenn ihr mir noch die Erwartungen nennt!

mfg
dolly999

[dolly999]

und ich wusste genau, dass mir keiner weiterhelfen kann.....!

[dolly999]

aber trotzdem immer

[Schmalzbacke]

The Medicines Company Reports Third Quarter 2003 Financial Results
Tuesday October 21, 4:39 pm ET


PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 21, 2003--The Medicines Company (Nasdaq:MDCO - News)
-- Revenues of $21.2 million increase 133% over third quarter
2002.

-- MDCO revises 2003 revenue guidance upward to $80-90 million
from $75-90 million.

-- REPLACE-2 results driving Angiomax(R) (bivalirudin) market
penetration.

The Medicines Company (Nasdaq:MDCO - News) today announced its financial results for the third quarter and first three quarters of 2003.

Financial highlights include:

Revenues of $21.2 million, compared to $9.1 million for the third quarter 2002. For the first three quarters of 2003, net revenue was $56.7 million, compared to $24.0 million for the same period in 2002.
Net loss of $6.2 million, compared to $11.2 million for the third quarter 2002. For the first three quarters of 2003, the net loss was $19.2 million, compared to $36.0 million for the same period in 2002.
Net loss per share of $0.13, compared to $0.29 for the third quarter in 2002. For the first three quarters of 2003, the net loss per share was $0.43, compared to $0.99 for the same period in 2002.
Recent operations highlights include:

Presentation of six-month patient follow-up results for the 6,002-patient REPLACE-2 clinical trial at the 2003 Transcatheter Cardiovascular Therapeutics (TCT) conference.
Submission of a supplemental New Drug Application to the U.S. Food and Drug Administration seeking an amended Angiomax product label to include data from the REPLACE and other programs.
Submission of a Market Authorization Application in Europe for Angiomax use in patients undergoing percutaneous coronary interventions.
Start of patient enrollment in the EVOLUTION and CHOOSE clinical trials of Angiomax use in coronary surgery.
Initiation of patient enrollment in the 13,800-patient ACUITY trial of Angiomax in patients presenting to the emergency department with acute coronary syndromes.
Completion of manufacturing commercial grade lots of Clevelox® (clevidipine).
Dave Stack, President and Chief Executive Officer of The Medicines Company, stated, "The significant increase in revenues for the third quarter indicates that Angiomax continues to gain market share versus heparin in coronary angioplasty. We believe this is attributable to the ease of use, safety, cost effectiveness and efficacy of Angiomax demonstrated in the REPLACE-2 trial`s 30-day and six month patient follow-up findings. We are today tightening our annual revenue guidance upward to $80-90 million from the $75-90 million range announced last quarter. Given the results of the first three-quarters of 2003, combined with our expectations for a strong fourth quarter, we believe we are on track to more than double our 2002 revenues in 2003."

There will be a conference call with management today at 5:00 p.m. to discuss the financial results and guidance for the remainder of 2003. To listen in: dial 800-472-8325 and request The Medicines Company financial results call.

From outside U.S.: dial 706-679-0816.

Replay available for two weeks following call: 800-642-1687.

Replay outside the U.S.: 706-645-9291. Replay passcode: 3206975.


About The Medicines Company: The Medicines Company meets the demands of the world`s most advanced medical practitioners by developing products that improve hospital acute care. The Company markets Angiomax® (bivalirudin), an anticoagulant approved in the U.S. and other countries for use in patients undergoing coronary angioplasty procedures. The Medicines Company creates value using its range of clinical and commercial skills to develop products acquired from leading life science innovators.

Statements contained in this press release about The Medicines Company`s position and the success of its products in the marketplace, its projected revenues for 2003, and the development of its products, and all other statements that are not purely historical, are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company`s actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute to such differences include the extent of the commercial success of Angiomax, whether the Company`s products will advance in the clinical trials process, whether the Company`s products will receive approval from regulatory agencies, physicians` acceptance of clinical trial results, and the Company`s ability to identify, select and acquire additional product candidates, as well as the risk factors detailed from time-to-time in the Company`s periodic reports and registration statements filed with the Securities and Exchange Commission including, without limitation, the risk factors detailed in the Company`s Quarterly Report on Form 10-Q filed on August 5, 2003, which are incorporated herein by reference. The Company specifically disclaims any obligation to update these forward-looking statements.

-0-

The Medicines Company
Condensed Consolidated Statements of Operations
Unaudited
Three months ended
(in thousands, except per share data) September 30,
----------------------
2003 2002
---------- ----------
Net revenue $ 21,248 $ 9,133
Operating expenses
Cost of revenue 6,602 2,227
Research and development 9,383 9,866
Selling, general and administrative 11,835 8,468
---------- ----------
Total operating expenses 27,820 20,561
---------- ----------
Loss from operations (6,572) (11,428)
Interest income, net 410 216
Net loss (6,162) (11,212)
========== ==========

Basic and diluted net loss per common share $ (0.13) $ (0.29)
========== ==========

Shares used in computing net loss per common
share:
Basic and diluted 47,130 39,162
========== ==========

-0-

Year-to-Date
September 30,
----------------------
(in thousands, except per share data) 2003 2002
---------- ----------
Net revenue $ 56,703 $ 24,004
Operating expenses
Cost of revenue 19,835 4,960
Research and development 24,836 28,567
Selling, general and administrative 32,191 27,199
---------- ----------
Total operating expenses 76,862 60,726
---------- ----------
Loss from operations (20,159) (36,722)
Interest income (expense), net 994 728
---------- ----------

Net loss (19,165) (35,994)
========== ==========
Basic and diluted net loss per common share $ (0.43) $ (0.99)
========== ==========
Shares used in computing net loss per common
share:
Basic and diluted 45,036 36,409
========== ==========

-0-

The Medicines Company
Condensed Consolidated Balance Sheets
Unaudited
Sept. 30, Dec. 31,
(in thousands) 2003 2002
---------- ----------
Assets
Cash, cash equivalents, available for sales
securities $ 126,877 $ 43,509
Accrued interest receivable 874 129
Accounts receivable, net 18,795 15,078
Inventories 6,426 14,179
Fixed assets, net 1,433 924
Other assets 1,399 895
---------- ----------
Total assets $ 155,804 $ 74,714
========== ==========

Liabilities and Stockholders` Equity
Current liabilities $ 18,784 $ 19,384
Deferred revenue 1,302 1,396
Stockholders` equity 135,718 53,934
---------- ----------
Total liabilities and stockholders` equity $ 155,804 $ 74,714
========== ==========



--------------------------------------------------------------------------------
Contact:
The Medicines Company, Parsippany
Michael Mitchell, 973-656-1616
[e-mail]




Welcome, maestrowm [Sign Out] Money Manager - My Yahoo! View - Customize
Financial News
Enter symbol(s) BasicPerformanceReal-time MktDetailedChartResearchOptionsOrder Book Symbol Lookup







Press Release Source: ViroLogic, Inc.


ViroLogic Announces Third Quarter 2003 Financial Results
Tuesday November 4, 4:05 pm ET
Company Reports Third Quarter Revenue of $9.1 million, an Increase of Over 50 Percent over Third Quarter of 2002


SOUTH SAN FRANCISCO, Calif., Nov. 4 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC - News) today reported financial results for the third quarter and nine months ended September 30, 2003.






The Company reported revenue of $9.1 million for the third quarter of 2003, an increase of 54 percent over revenue of $5.9 million for the third quarter of 2002. The growth was attributed to continuing steady performance of the Company`s patient testing products, which rose to $6.2 million in the third quarter of 2003 from $4.6 million in the third quarter of 2002, an increase of 35 percent. The growth was further enhanced this quarter by increases in pharmaceutical drug development and NIH grant revenues.

Gross margin was 50 percent in the third quarter of 2003 compared to 39 percent reported during the same quarter last year. Operating costs and expenses for the third quarter of 2003 were $9.6 million, compared to $11.5 million for the same period in 2002. The decrease in operating costs and expenses was the result of a company-wide focus to increase efficiencies and achieve improved economies of scale, partially offset by higher costs associated with increasing testing volume. Gross margin improvement was also driven by an increased contribution from pharmaceutical revenue during the third quarter.

Net loss for the third quarter of 2003 was $0.4 million, or $0.01 per common share, compared to a net loss of $5.6 million, or $0.23 per common share, for the same period in 2002.

In the third quarter of 2003, the Company recorded stock dividends to preferred stockholders of $0.4 million, resulting in net loss applicable to common stockholders of $0.02 per common share. In the third quarter of 2002, the Company recorded stock dividends to preferred stockholders of $0.2 million, resulting in net loss applicable to common stockholders of $0.24 per common share.

Nine Month Results

The Company reported revenue of $24.0 million for the first nine months of 2003, an increase of 31 percent over revenue of $18.3 million for the same period of 2002. Operating costs and expenses for the first nine months of 2003 were $29.3 million, compared to $35.8 million for the same period of 2002. This decrease was the result of ongoing operational improvements and economies of scale, and was partially offset by higher costs associated with increasing testing volume.

Net loss for the first nine months of 2003 was $5.1 million, or $0.17 per common share, compared to a net loss of $17.2 million, or $0.74 per common share, for the same period in 2002.

In the first nine months of 2003, the Company recorded a non-cash deemed dividend to preferred stockholders of $2.2 million resulting from a warrant exchange approved by the Company`s stockholders on February 4, 2003 relating to the sale of Series C convertible preferred stock, and recorded stock dividends to preferred stockholders of $1.4 million, resulting in net loss applicable to common stockholders of $0.28 per common share. In the first nine months of 2002, the Company recorded a non-cash deemed dividend to preferred stockholders of $2.9 million from the sale of Series B convertible preferred stock, and recorded stock dividends to preferred stockholders of $0.7 million, resulting in net loss applicable to common stockholders of $0.89 per common share.

The Company had $9.1 million of cash, restricted cash and short-term investments at September 30, 2003.

"We believe we are on track to achieve near the middle of our projected $32 to $36 million revenue range for 2003," said Bill Young, Chairman and CEO of ViroLogic. "We continue to focus our efforts on revenue generating activities in our patient testing and pharmaceutical drug development businesses. At the same time, our pragmatic expense management has led to a significantly reduced net loss and, combined with growing revenues, increased gross margin. This should enable us to generate cash from operating activities at a quarterly revenue run rate of approximately $10 to $11 million. While we will be providing full year 2004 guidance on our fourth quarter and year end conference call in February 2004, preliminarily we expect annual revenue growth that is consistent with levels we have achieved over the last two years. On the expense side, we plan to leverage the efficiencies of our existing infrastructure and scale operations to further grow our business, and build sustainable long-term profitability."

Recent Achievements
-- ViroLogic was ranked number 19 on the 2003 Deloitte Technology Fast
500, a list of the 500 fastest growing technology companies in North
America, based on revenue growth for the years 1998 - 2002.
-- ViroLogic was awarded a grant from the National Institute of Allergy
and Infectious Diseases (NIAID), a division of the U.S. National
Institutes of Health, to develop a Hepatitis C virus (HCV) drug
susceptibility assay. This grant award follows three previously
announced NIH grants to ViroLogic and brings the total grant awards
announced this quarter to more than $4 million to be funded over three
years.
-- ViroLogic announced the publication of updated guidelines from the
International AIDS Society USA (IAS-USA) and the U.S. Department of
Health and Human Services (DHHS) further supporting the value and
importance of resistance testing as a means to improve virologic
outcome among HIV infected individuals.
-- ViroLogic researchers and collaborators presented four studies using
the Company`s technology at the 43rd ICAAC in September, including a
presentation by Dr. Eric S. Daar, M.D., Director, Division of HIV
Medicine, Harbor-UCLA Research and Education Institute and Associate
Professor of Medicine, David Geffen School of Medicine at UCLA, Los
Angeles, which outlined the statistical analysis of data demonstrating
the utility of HIV Co-Receptor Tropism and Replication Capacity, a
gauge of "viral fitness," as predictors of clinical progression to
AIDS.
-- ViroLogic promoted Ken Hitchner to the position of Vice President,
Pharmaceutical Collaborations.


Conference Call Details

ViroLogic will hold a conference call today at 5:00 p.m. ET to discuss third quarter 2003 earnings results. The call will be hosted by Mr. Bill Young, Chairman & CEO of ViroLogic, Inc. To participate in the teleconference, please call 800-299-8538 fifteen minutes before the conference begins and ask to be connected to the ViroLogic teleconference. International callers please dial 617-786-2902. The call will also be webcast live at http://www.virologic.com/webcast.html. Please see web site for details.

About ViroLogic

ViroLogic is a biotechnology company advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious viral diseases such as AIDS and hepatitis. The Company`s products are designed to help doctors optimize treatment regimens that lead to better patient outcomes and reduced costs. ViroLogic`s technology is also being used by numerous biopharmaceutical companies to develop new and improved anti-viral therapeutics and vaccines targeted at emerging drug-resistant viruses. More information about the Company and its technology can be found on its web site at www.virologic.com.

Certain statements in this press release are forward-looking, including statements relating to anticipated growth in sales of testing products and ongoing benefits from cost reduction measures, expectations regarding 2003 and 2004 guidance, the development of new technology, the receipt of non-dilutive grants, projected operating results, continued acceptance of the Company`s products for patient testing and increasing demand from vaccine and drug development partners. These risks and uncertainties include, but are not limited to, the risk that the Company`s products for patient testing may not continue to be accepted or that increased demand from drug development partners may not develop as anticipated, the risk that ViroLogic may not continue to realize anticipated benefits from its cost-cutting measures, the timing of pharmaceutical company clinical trials, whether payors will authorize reimbursement for its products, whether the FDA or any other agency will decide to regulate ViroLogic`s products or services, whether the Company will encounter problems or delays in automating its processes, whether ViroLogic successfully introduces new products, whether others introduce competitive products, whether intellectual property underlying the Company`s PhenoSense technology is adequate, whether licenses to third party technology will be available, whether ViroLogic is able to build brand loyalty and expand revenues, and whether ViroLogic will be able to raise sufficient capital when required. For a discussion of other factors that may cause ViroLogic`s actual events to differ from those projected, please refer to the Company`s most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission.

VIROLOGIC, INC.
SELECTED FINANCIAL DATA
(In thousands, except per share amounts)

Three months ended Nine months ended
September 30, September 30,
2003 2002 2003 2002
(Unaudited) (Unaudited)
Statement of Operations Data:
Revenue (a) $9,125 $5,927 $24,046 $18,292
------- ------- -------- --------
Operating costs and expenses:
Cost of product revenue 4,403 3,463 12,490 10,649
Research and development 1,090 2,469 3,525 8,286
General and administrative 2,113 2,279 6,954 7,661
Sales and marketing 1,990 3,333 6,301 9,181
------- ------- -------- ---------
Total operating costs and
expenses 9,596 11,544 29,270 35,777
------- ------- -------- --------
Operating loss (471) (5,617) (5,224) (17,485)
Interest income 22 54 85 252
Interest expense (32) (75) (120) (246)
Other income 52 52 156 295
------- -------- -------- --------
Net loss (429) (5,586) (5,103) (17,184)
Deemed dividend to preferred
stockholders -- -- (2,155) (2,860)
Preferred stock dividend (413) (249) (1,386) (715)
------- ------- -------- --------
Net loss applicable to common
stockholders $(842) $(5,835) $(8,644) $(20,759)
==== ==== ===== =====
Basic and diluted amounts per
common share:
Net loss $(0.01) $(0.23) $(0.17) $(0.74)
Dividends to preferred
stockholders (0.01) (0.01) (0.11) (0.15)
------- ------- -------- -------
Net loss applicable to common
stockholders $(0.02) $(0.24) $(0.28) $(0.89)
==== ==== ===== ====
Weighted average shares used in
computing basic and diluted net
loss per common share 34,365 24,695 30,809 23,449


September 30, December 31,
2003 2002 (b)
(Unaudited)
Balance Sheet Data
Cash, cash equivalents and short-term
investments $8,285 $11,145
Accounts receivable, net 5,109 4,924
Working capital 11,017 (239)
Restricted cash 776 707
Total assets 26,805 30,486
Long term obligations, less current portion 169 419
Redeemable convertible preferred stock 3,880 4,249
Total stockholders` equity $17,111 $7,014

(a) Revenue for the three and nine months period ended September 30, 2003
includes contract revenue of $366,000 and $950,000 compared to
$255,000 and $697,000 for the corresponding periods in 2002. Contract
revenue consists of NIH grant, commercial development and other
revenue. The costs associated with contract revenue for the three and
nine months ended September 30, 2003 totaled $432,000 and $767,000
compared to $255,000 and $697,000 for the corresponding periods in
2002, and are included in research and development expenses.
(b) The balance sheet data is derived from audited financial statements
for the year ended December 31, 2002, included in the Company`s Annual
Report on Form 10-K filed with the Securities and Exchange Commission.




--------------------------------------------------------------------------------
Source: ViroLogic, Inc.